X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2980) 2980
ranibizumab (2963) 2963
ophthalmology (2489) 2489
angiogenesis inhibitors - therapeutic use (1918) 1918
male (1885) 1885
female (1883) 1883
vascular endothelial growth factor a - antagonists & inhibitors (1634) 1634
aged (1624) 1624
intravitreal injections (1617) 1617
bevacizumab (1581) 1581
macular degeneration (1531) 1531
middle aged (1273) 1273
tomography, optical coherence (1071) 1071
aged, 80 and over (1058) 1058
vascular endothelial growth factor (1049) 1049
treatment outcome (905) 905
visual acuity - physiology (901) 901
retrospective studies (850) 850
fluorescein angiography (812) 812
antibodies, monoclonal, humanized - therapeutic use (804) 804
endothelial growth-factor (734) 734
macular degeneration - drug therapy (700) 700
visual acuity (699) 699
choroidal neovascularization - drug therapy (655) 655
wet macular degeneration - drug therapy (654) 654
ranibizumab - therapeutic use (628) 628
diabetic retinopathy (622) 622
eye diseases (600) 600
antibodies, monoclonal, humanized (555) 555
follow-up studies (553) 553
genetic structures (542) 542
macular edema - drug therapy (522) 522
angiogenesis inhibitors - administration & dosage (499) 499
care and treatment (491) 491
age-related macular degeneration (490) 490
photodynamic therapy (488) 488
prospective studies (488) 488
antibodies, monoclonal - therapeutic use (484) 484
choroidal neovascularization (481) 481
retina (452) 452
edema (435) 435
therapy (421) 421
verteporfin (399) 399
diabetes (393) 393
physiological aspects (393) 393
age (391) 391
optical coherence tomography (386) 386
neovascularization (385) 385
adult (382) 382
diabetic retinopathy - drug therapy (376) 376
injection (360) 360
recombinant fusion proteins - therapeutic use (359) 359
aflibercept (358) 358
patients (347) 347
sense organs (343) 343
receptors, vascular endothelial growth factor - therapeutic use (329) 329
analysis (324) 324
wet macular degeneration - physiopathology (323) 323
angiogenesis inhibitors - adverse effects (321) 321
retinopathy (315) 315
abridged index medicus (302) 302
drug therapy (299) 299
eye (292) 292
vegf (290) 290
medicine & public health (285) 285
research (285) 285
studies (277) 277
visual acuity - drug effects (277) 277
bevacizumab - therapeutic use (274) 274
intravitreal bevacizumab (272) 272
medical imaging (271) 271
photochemotherapy (270) 270
wet macular degeneration - diagnosis (266) 266
safety (264) 264
choroidal neovascularization - etiology (255) 255
animals (250) 250
clinical trials (248) 248
pharmacology & pharmacy (247) 247
macular edema (245) 245
antibodies, monoclonal, humanized - administration & dosage (238) 238
choroidal neovascularization - diagnosis (235) 235
endothelial growth factors (235) 235
angiogenesis (234) 234
diabetic macular edema (234) 234
risk factors (233) 233
anti-vegf (230) 230
retina - pathology (229) 229
efficacy (226) 226
injections (215) 215
choroidal neovascularization - physiopathology (214) 214
combined modality therapy (206) 206
prevalence (206) 206
acuity (204) 204
macular edema - etiology (201) 201
intravitreal injection (197) 197
outcomes (196) 196
surgery (195) 195
intravitreal ranibizumab (193) 193
macular edema - physiopathology (192) 192
trial (187) 187
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3454) 3454
German (56) 56
Spanish (42) 42
French (38) 38
Portuguese (27) 27
Chinese (13) 13
Japanese (11) 11
Russian (7) 7
Czech (6) 6
Hungarian (3) 3
Polish (3) 3
Swedish (3) 3
Danish (2) 2
Hebrew (2) 2
Italian (2) 2
Norwegian (2) 2
Turkish (2) 2
Dutch (1) 1
Icelandic (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cochrane Database of Systematic Reviews, ISSN 1469-493X, 10/2018, Volume 2018, Issue 10, p. CD007419
Background Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Antiangiogenic therapy with anti‐vascular endothelial growth factor... 
Endocrine & metabolic | Receptors, Vascular Endothelial Growth Factor | Vascular Endothelial Growth Factor A | Macular oedema | Laser Coagulation | Visual Acuity | Retinal disease | Angiogenesis Inhibitors | Recombinant Fusion Proteins | Bevacizumab | Randomized Controlled Trials as Topic | Diabetic eye disease | Aptamers, Nucleotide | Ranibizumab | Quality of Life | Macular Edema | Diabetes | Eyes & vision | Network Meta‐Analysis | Triamcinolone | Medicine General & Introductory Medical Sciences | Diabetic Retinopathy | Retinal disease (including age‐related macular degeneration) | CLINICAL-TRIAL | RANIBIZUMAB PLUS PROMPT | RANDOMIZED CONTROLLED-TRIAL | Receptors, Vascular Endothelial Growth Factor [therapeutic use] | DEFERRED LASER | MEDICINE, GENERAL & INTERNAL | PEGAPTANIB SODIUM | Bevacizumab [adverse effects; therapeutic use] | Laser Coagulation [methods] | Aptamers, Nucleotide [adverse effects; therapeutic use] | Network Meta-Analysis | QUALITY-OF-LIFE | Macular Edema [drug therapy; etiology; surgery] | Vascular Endothelial Growth Factor A [antagonists & inhibitors] | Visual Acuity [drug effects; physiology] | COST-EFFECTIVENESS | Angiogenesis Inhibitors [adverse effects; therapeutic use] | LASER PHOTOCOAGULATION | Ranibizumab [adverse effects; therapeutic use] | Recombinant Fusion Proteins [adverse effects; therapeutic use] | INTRAVITREAL BEVACIZUMAB | Diabetic Retinopathy [complications] | Triamcinolone [adverse effects; therapeutic use] | VEGF TRAP-EYE | Bevacizumab - therapeutic use | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Recombinant Fusion Proteins - adverse effects | Bevacizumab - adverse effects | Humans | Recombinant Fusion Proteins - therapeutic use | Ranibizumab - therapeutic use | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Diabetic Retinopathy - complications | Macular Edema - etiology | Ranibizumab - adverse effects | Visual Acuity - drug effects | Triamcinolone - adverse effects | Laser Coagulation - methods | Angiogenesis Inhibitors - therapeutic use | Angiogenesis Inhibitors - adverse effects | Triamcinolone - therapeutic use | Visual Acuity - physiology | Aptamers, Nucleotide - therapeutic use | Aptamers, Nucleotide - adverse effects | Macular Edema - surgery | Macular Edema - drug therapy
Journal Article
Cochrane database of systematic reviews, ISSN 1469-493X, 2014, Volume 8, Issue 8, p. CD005139
Journal Article
Cochrane database of systematic reviews, ISSN 1469-493X, 06/2017, Volume 2017, Issue 6, p. CD007419
Background Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Antiangiogenic therapy with anti-vascular endothelial growth factor... 
DA VINCI | Macular Edema [drug therapy surgery] | Growth Factor [therapeutic use] | Humans | RANIBIZUMAB PLUS PROMPT | Receptors, Vascular Endothelial | RANDOMIZED CONTROLLED-TRIAL | Bevacizumab | DEFERRED LASER | Antibodies, Monoclonal, Humanized [therapeutic use] | MEDICINE, GENERAL & INTERNAL | Recombinant Fusion Proteins [therapeutic use] | PEGAPTANIB SODIUM | Angiogenesis Inhibitors [therapeutic use] | Laser Coagulation [methods] | Ranibizumab | QUALITY-OF-LIFE | Vascular Endothelial Growth Factor A [antagonists & inhibitors] | COST-EFFECTIVENESS | Triamcinolone [therapeutic use] | LASER PHOTOCOAGULATION | Randomized Controlled Trials as Topic | Antibodies, Monoclonal [therapeutic use] | Aptamers, Nucleotide [therapeutic use] | INTRAVITREAL BEVACIZUMAB | Diabetic Retinopathy [complications] | VEGF TRAP-EYE | Bevacizumab - therapeutic use | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Recombinant Fusion Proteins - adverse effects | Bevacizumab - adverse effects | Recombinant Fusion Proteins - therapeutic use | Ranibizumab - therapeutic use | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Diabetic Retinopathy - complications | Macular Edema - etiology | Ranibizumab - adverse effects | Visual Acuity - drug effects | Triamcinolone - adverse effects | Laser Coagulation - methods | Angiogenesis Inhibitors - therapeutic use | Network Meta-Analysis | Angiogenesis Inhibitors - adverse effects | Triamcinolone - therapeutic use | Visual Acuity - physiology | Aptamers, Nucleotide - therapeutic use | Aptamers, Nucleotide - adverse effects | Macular Edema - surgery | Macular Edema - drug therapy | Quality of Life
Journal Article
Journal Article
American Family Physician, ISSN 0002-838X, 2016, Volume 94, Issue 3, pp. 219 - 226
Journal Article
Cochrane library, ISSN 1469-493X, 2019, Volume 2019, Issue 3, p. CD005139
Background Age‐related macular degeneration (AMD) is the most common cause of uncorrectable severe vision loss in people aged 55 years and older in the... 
Choroidal Neovascularization | Vascular Endothelial Growth Factor A | Intravitreal Injections | Antibodies, Monoclonal | Visual Acuity | Retinal disease | Angiogenesis Inhibitors | Bevacizumab | Randomized Controlled Trials as Topic | Antibodies, Monoclonal, Humanized | Aptamers, Nucleotide | Ranibizumab | Age‐related macular degeneration | Eyes & vision | Medicine General & Introductory Medical Sciences | Macular Degeneration | Retinal disease (including age‐related macular degeneration) | VISUAL-ACUITY | Humans | Middle Aged | RANDOMIZED CLINICAL-TRIAL | RANIBIZUMAB TREATMENT | VISION-RELATED FUNCTION | BEVACIZUMAB AVASTIN THERAPY | Antibodies, Monoclonal, Humanized [therapeutic use] | MEDICINE, GENERAL & INTERNAL | COST-UTILITY ANALYSIS | Angiogenesis Inhibitors [therapeutic use] | Verteporfin | OPTICAL COHERENCE TOMOGRAPHY | Vascular Endothelial Growth Factor A [antagonists &inhibitors] | Porphyrins [therapeutic use] | Antibodies, Monoclonal [therapeutic use] | Aged | VERTEPORFIN PHOTODYNAMIC THERAPY | Aptamers, Nucleotide [therapeutic use] | Visual Acuity [drug effects] | INTRAVITREAL BEVACIZUMAB | Macular Degeneration [drug therapy] | Antibodies, Monoclonal, Humanized - therapeutic use | Bevacizumab - therapeutic use | Antibodies, Monoclonal - therapeutic use | Aptamers, Nucleotide - therapeutic use | Ranibizumab - therapeutic use | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Macular Degeneration - drug therapy | Visual Acuity - drug effects | Angiogenesis Inhibitors - therapeutic use
Journal Article